Artificial intelligence-assisted spatial omics-based biomimetic nanoplatform for intelligent and precise intervention in the immunosuppressive core region of ovarian cancer

1. Reid, B. M., Permuth, J. B. & Sellers, T. A. Epidemiology of ovarian cancer: a review. Cancer Biol. Med. 14, 9-32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084 (2017).

2. Mikulak, J. et al. Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics. Cell Death Dis. https://doi.org/10.1038/s41419-025-07557-5 (2025).

3. Yang, B. & Dai, M. High-dimensional deconstruction of ovarian cancer at single-cell precision reveals HEBP2 that reshape the TIME and drive carboplatin resistance. Transl. Oncol. 44, 101917 (2024).

   Google Scholar 

4. Zhao, Q. Single-cell RNA sequencing in ovarian cancer: revealing new perspectives in the tumor microenvironment. Am. J. Transl. Res. 16, 3338–3354 (2024).

   Google Scholar 

5. Chen, Q., Zhang, Y., Wang, C., Ding, H. & Chi, L. Integrated analysis of single-cell and bulk transcriptome reveals hypoxia-induced immunosuppressive microenvironment to predict immunotherapy response in high-grade serous ovarian cancer. Front. Pharmacol. https://doi.org/10.3389/fphar.2024.1450751 (2024).

6. Kader, T. et al. Multimodal spatial profiling reveals immune suppression and microenvironment remodeling in fallopian tube precursors to high-grade serous ovarian carcinoma. Cancer Discov. 15, 1180–1202 (2024).

   Google Scholar 

7. Li, S., Wang, Z. & Huang, H.-D. Deciphering ovarian cancer heterogeneity through spatial transcriptomics, single-cell profiling, and copy number variations. PLoS One 20, e0317115 (2025).

   Google Scholar 

8. Wang, Y., Zhou, H., Ju, S., Dong, X. & Zheng C. The solid tumor microenvironment and related targeting strategies: a concise review. Front. Immunol. https://doi.org/10.3389/fimmu.2025.1563858 (2025).

9. Feng, Q.-S., Shan, X.-F., Yau, V., Cai, Z.-G. & Xie, S. Facilitation of tumor stroma-targeted therapy: model difficulty and co-culture organoid method. Pharmaceuticals 18, 62 (2025).

   Google Scholar 

10. Ghisoni, E. et al. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. Nat. Rev. Clin. Oncol. 21, 801–817 (2024).

    Google Scholar 

11. Xia, W., Tan, Y., Liu, Y., Xie, N. & Zhu, H. Prospect of extracellular vesicles in tumor immunotherapy. Front. Immunol. https://doi.org/10.3389/fimmu.2025.1525052 (2025).

12. Dai, Y., Yao, Y., He, Y. & Hu, X. Role of vascular endothelium and exosomes in cancer progression and therapy (review). Int. J. Oncol. https://doi.org/10.3892/ijo.2024.5712 (2024).

13. Molefi, T., Mabonga, L., Hull, R., Sebitloane, M. & Dlamini, Z. From genes to clinical practice: exploring the genomic underpinnings of endometrial cancer. Cancers 17, 320 (2025).

    Google Scholar 

14. Chadokiya, J. et al. Advancing precision cancer immunotherapy drug development, administration, and response prediction with AI-enabled Raman spectroscopy. Front. Immunol. https://doi.org/10.3389/fimmu.2024.1520860 (2025).

15. Youssef, E., Palmer, D., Fletcher, B. & Vaughn, R. Exosomes in precision oncology and beyond: from bench to bedside in diagnostics and therapeutics. Cancers 17, 940 (2025).

    Google Scholar 

16. Yuan, Q., Jia, L., Yang, J. & Li, W. The role of macrophages in liver metastasis: mechanisms and therapeutic prospects. Front. Immunol. https://doi.org/10.3389/fimmu.2025.1542197 (2025).

17. Xiong, Z., Huang, Y., Cao, S., Huang, X. & Zhang, H. A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment. Front. Immunol. https://doi.org/10.3389/fimmu.2025.1542326 (2025).

18. Liu, J., Li, X., Li, Y., Gong, Q. & Luo, K. Metformin-based nanomedicines for reprogramming tumor immune microenvironment. Theranostics 15, 993–1016 (2025).

    Google Scholar 

19. Turlej, E. et al. Cross-talk between cancer and its cellular environment—a role in cancer progression. Cells 14, 403 (2025).

    Google Scholar 

20. Huang, T., Li, F., Wang, Y., Gu, J. & Lu, L. Tumor-infiltrating regulatory T cell: a promising therapeutic target in tumor microenvironment. Chin. Med. J. 137, 2996–3009 (2024).

    Google Scholar 

21. Pawłowska, A. et al. Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors. IJMS 24, 10859 (2023).

    Google Scholar 

22. Sabit, H. et al. Leveraging single-cell multi-omics to decode tumor microenvironment diversity and therapeutic resistance. Pharmaceuticals 18, 75 (2025).

    Google Scholar 

23. Liu, Q. et al. GNA15 predicts poor outcomes as a novel biomarker related to M2 macrophage infiltration in ovarian cancer. Front. Immunol. https://doi.org/10.3389/fimmu.2025.1512086 (2025).

24. Wu, J. et al. Innate immune cells in vascular lesions: mechanism and significance of diversified immune regulation. Ann. Med. https://doi.org/10.1080/07853890.2025.2453826 (2025).

25. Gao, Y. et al. Single-cell RNA sequencing reveals the intra-tumoral heterogeneity and immune microenvironment of small cell carcinoma of the ovary, hypercalcemic type. J. Ovarian Res. https://doi.org/10.1186/s13048-025-01649-8 (2025).

26. Tan, H. et al. Harnessing macrophages in cancer therapy: from immune modulators to therapeutic targets. Int. J. Biol. Sci. 21, 2235–2257 (2025).

    Google Scholar 

27. Wang, C. et al. Immunosuppressive JAG2 + tumor-associated neutrophils hamper PD-1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells. Cancer Commun. 45, 747–773 (2025).

    Google Scholar 

28. Liu, K. et al. Epigenetic regulation of stromal and immune cells and therapeutic targets in the tumor microenvironment. Biomolecules 15, 71 (2025).

    Google Scholar 

29. Zheng, F. et al. Breaking immunosuppression to enhance cancer stem cell-targeted immunotherapy. Int. J. Biol. Sci. 21, 1819–1836 (2025).

    Google Scholar 

30. Liu, S., Liu, C., He, Y., Li, J. Benign non-immune cells in tumor microenvironment. Front. Immunol. https://doi.org/10.3389/fimmu.2025.1561577 (2025).

31. Remley, V. A., Linden, J., Bauer, T. W. & Dimastromatteo, J. Unlocking antitumor immunity with adenosine receptor blockers. Cancer Drug Resist. 6, 748–767 (2023).

    Google Scholar 

32. Xun, Z. et al. Identification of hypoxia-ALCAMhigh macrophage- exhausted T cell axis in tumor microenvironment remodeling for immunotherapy resistance. Adv. Sci. https://doi.org/10.1002/advs.202309885 (2024).

33. Rosario, S. R. et al. Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer. Nat Commun. https://doi.org/10.1038/s41467-024-54565-8 (2024).

34. Bai, R. et al. The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol. Cancer. https://doi.org/10.1186/s12943-022-01645-2 (2022).

35. Wang, X. et al. HIF-1α is a rational target for future ovarian cancer therapies. Front. Oncol. https://doi.org/10.3389/fonc.2021.785111 (2021).

36. Guo, N. et al. CD8 + T cell infiltration is associated with improved survival and negatively correlates with hypoxia in clear cell ovarian cancer. Sci. Rep. https://doi.org/10.1038/s41598-023-30655-3 (2023).

37. Fan, P. et al. Alleviating hypoxia to improve cancer immunotherapy. Oncogene 42, 3591–3604 (2023).

    Google Scholar 

38. Langsten, K. L., Kim, J. H., Sarver, A. L., Dewhirst, M., Modiano, J. F. Comparative approach to the temporo-spatial organization of the tumor microenvironment. Front. Oncol. https://doi.org/10.3389/fonc.2019.01185 (2019).

39. Chap, B. S., Rayroux, N., Grimm, A. J., Ghisoni, E. & Dangaj Laniti, D. Crosstalk of T cells within the ovarian cancer microenvironment. Trends Cancer 10, 1116–1130 (2024).

    Google Scholar 

40. Blanc-Durand, F., Clemence Wei Xian, L. & Tan, D. S. P. Targeting the immune microenvironment for ovarian cancer therapy. Front. Immunol. https://doi.org/10.3389/fimmu.2023.1328651 (2023).

41. Gao, W. et al. SPP1 is a prognostic related biomarker and correlated with tumor-infiltrating immune cells in ovarian cancer. BMC Cancer. https://doi.org/10.1186/s12885-022-10485-8 (2022).

42. Kozłowski, M., Borzyszkowska, D. & Cymbaluk-Płoska, A. The role of TIM-3 and LAG-3 in the microenvironment and immunotherapy of ovarian cancer. Biomedicines 10, 2826 (2022).

    Google Scholar 

43. González, J. A., Wrobel, J., Vandekar, S. & Moraga, P. Analyzing spatial point patterns in digital pathology: immune cells in high-grade serous ovarian carcinomas. Am. Statistician 79, 355–370 (2025).

    Google Scholar 

44. Jiang, X. et al. Single-cell RNA sequencing and cell–cell communication analysis reveal tumor microenvironment associated with chemotherapy responsiveness in ovarian cancer. Clin. Transl. Oncol. 27, 1000–1012 (2024).

    Google Scholar 

45. Luo, H., Wang, K. & Li, B. Integrating single-cell and spatial transcriptomic analysis to unveil heterogeneity in high-grade serous ovarian cancer. Front. Immunol. https://doi.org/10.3389/fimmu.2024.1420847 (2024).

46. Sang-aram, C., Browaeys, R., Seurinck, R. & Saeys, Y. Unraveling cell–cell communication with NicheNet by inferring active ligands from transcriptomics data. Nat. Protoc. 20, 1439–1467 (2025).

    Google Scholar 

47. Li, Z. et al. Unveiling the novel immune and molecular signatures of ovarian cancer: insights and innovations from single-cell sequencing. Front. Immunol. https://doi.org/10.3389/fimmu.2023.1288027 (2023).

48. Kampan, N. C. et al. Combining TNFR2-expressing Tregs and IL-6 as superior diagnostic biomarkers for high-grade serous ovarian cancer masses. Cancers 15, 667 (2023).

    Google Scholar 

49. Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643–1660.e17 (2020).

    Google Scholar 

50. Verona, F. et al. Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction. Front. Immunol. https://doi.org/10.3389/fimmu.2025.1529847 (2025).

51. Chu, X., Tian, Y. & Lv, C. Decoding the spatiotemporal heterogeneity of tumor-associated macrophages. Mol. Cancer. https://doi.org/10.1186/s12943-024-02064-1 (2024).

52. Qian, Y., Yin, Y., Zheng, X., Liu, Z. & Wang X. Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities. Biomark Res. https://doi.org/10.1186/s40364-023-00549-7 (2024).

53. Li, D. et al. The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways. Cell Commun Signal. https://doi.org/10.1186/s12964-024-01776-7 (2024).

54. Xiao, Y., Bi, M., Guo, H. & Li, M. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis. eBioMedicine 79, 104001 (2022).

    Google Scholar 

55. Zhuo, L., Meng, F., Sun, K., Zhou, M. & Sun, J. Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis. Br. J. Cancer 131, 1068–1079 (2024).

    Google Scholar 

56. Hornburg, M., Desbois, M. & Lu, S. et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 39, 928-944.e6. https://doi.org/10.1016/j.ccell.2021.04.004 (2021).

57. Feng, Q. et al. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat. Commun. https://doi.org/10.1038/s41467-022-32521-8 (2022).

58. Granja, J. M. et al. ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis. Nat. Genet. 53, 403–411 (2021).

    Google Scholar 

59. Ji, Y. et al. The epigenetic hallmarks of immune cells in cancer. Mol. Cancer. https://doi.org/10.1186/s12943-025-02255-4 (2025).

60. Pang, L. et al. Epigenetic regulation of tumor immunity. Journal of Clinical Investigation. https://doi.org/10.1172/jci178540 (2024).

61. Xie, X., Liu, W., Yuan, Z., Chen, H. & Mao, W. Bridging epigenomics and tumor immunometabolism: molecular mechanisms and therapeutic implications. Mol. Cancer. https://doi.org/10.1186/s12943-025-02269-y (2025).

62. Zhao, F. et al. Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies. Front. Immunol. https://doi.org/10.3389/fimmu.2024.1500153 (2025).

63. Chen, Y. et al. Aldehyde dehydrogenase 2-mediated aldehyde metabolism promotes tumor immune evasion by regulating the NOD/VISTA axis. J. Immunother. Cancer 11, e007487 (2023).

    Google Scholar 

64. Burgess, D. J. Spatial transcriptomics coming of age. Nat. Rev. Genet. 20, 317–317 (2019).

    Google Scholar 

65. Marx, V. Method of the Year: spatially resolved transcriptomics. Nat. Methods 18, 9–14 (2021).

    Google Scholar 

66. Cipurko, D., Ueda, T., Mei, L. & Chevrier, N. Repurposing large-format microarrays for scalable spatial transcriptomics. Nat. Methods 22, 145–155 (2024).

    Google Scholar 

67. Winkler, M., Malhotra, N., & Mistarz, A. et al. Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer. Immunohorizons. 10, vlaf084. https://doi.org/10.1093/immhor/vlaf084 (2026).

68. Launonen, I.-M. et al. Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer. Cancer Cell 42, 2045–2063.e10 (2024).

    Google Scholar 

69. Kzhyshkowska, J., Shen, J. & Larionova, I. Targeting of TAMs: Can we be more clever than cancer cells?. Cell Mol. Immunol. 21, 1376–1409 (2024).

    Google Scholar 

70. Wang, N. et al. Next-generation spatial transcriptomics: unleashing the power to gear up translational oncology. MedComm. https://doi.org/10.1002/mco2.765 (2025).

71. Wang, Q. et al. Spatially resolved transcriptomics technology facilitates cancer research. Adv. Sci. https://doi.org/10.1002/advs.202302558 (2023).

72. Jing, S. et al. Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments. npj Precis. Onc. https://doi.org/10.1038/s41698-025-00857-1 (2025).

73. Bao, X., Bai, X., Liu, X., Shi, Q. & Zhang, C. Spatially informed graph transformers for spatially resolved transcriptomics. Commun Biol. https://doi.org/10.1038/s42003-025-08015-w (2025).

74. Xing, L. et al. The biological roles of CD47 in ovarian cancer progression. Cancer Immunol. Immunother. https://doi.org/10.1007/s00262-024-03708-3 (2024).

75. Park, J., Choi, J., Lee, J. E., Choi, H. & Im, H. J. Spatial Transcriptomics-Based Identification of Molecular Markers for Nanomedicine Distribution in Tumor Tissue. Small Methods. 6, e2201091. https://doi.org/10.1002/smtd.202201091 (2022).

76. Ferri-Borgogno, S. et al. Spatial transcriptomics depict ligand–receptor cross-talk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors. Cancer Res. 83, 1503–1516 (2023).

    Google Scholar 

77. Chowdhury, S. et al. Learning directed acyclic graphs for ligands and receptors based on spatially resolved transcriptomic data of ovarian cancer. Brief. Bioinformatics. https://doi.org/10.1093/bib/bbaf085 (2025).

78. Zhu, J. et al. Mapping cellular interactions from spatially resolved transcriptomics data. Nat. Methods 21, 1830–1842 (2024).

    Google Scholar 

79. Li, W., Wang, H., Zhao, J., Xia, J. & Sun, X. scHyper: reconstructing cell–cell communication through hypergraph neural networks. Brief. Bioinform. https://doi.org/10.1093/bib/bbae436 (2024).

80. Liu, Y. et al. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer Cell 43, 905–924.e6 (2025).

    Google Scholar 

81. Wei, J. et al. Intercellular molecular crosstalk networks within invasive and immunosuppressive tumor microenvironment subtypes associated with clinical outcomes in four cancer types. Biomedicines 11, 3057 (2023).

    Google Scholar 

82. Hu, Y. et al. INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer. npj Precis. Onc. https://doi.org/10.1038/s41698-024-00523-y (2024).

83. Liu, Y. et al. Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma. Nat. Commun. https://doi.org/10.1038/s41467-024-52153-4 (2024).

84. Liu, S. et al. Single-cell and spatial transcriptomic profiling revealed niche interactions sustaining growth of endometriotic lesions. Cell Genomics 5, 100737 (2025).

    Google Scholar 

85. Deng, Y. et al. Single-cell RNA-sequencing atlas reveals the tumor microenvironment of metastatic high-grade serous ovarian carcinoma. Front. Immunol. https://doi.org/10.3389/fimmu.2022.923194 (2022).

86. Ma, C. et al. Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment. Mol. Cancer. https://doi.org/10.1186/s12943-023-01876-x (2023).

87. Zhang, S. & Wang, H. Targeting the lung tumour stroma: harnessing nanoparticles for effective therapeutic interventions. J. Drug Target. 33, 60–86 (2024).

    Google Scholar 

88. Liao, T. et al. Regulation of cancer-associated fibroblasts for enhanced cancer immunotherapy using advanced functional nanomedicines: an updated review. J. Nanobiotechnol. https://doi.org/10.1186/s12951-025-03217-0 (2025).

89. Thomas, M. R. et al. Navigating tumor microenvironment barriers with nanotherapeutic strategies for targeting metastasis. Adv. Healthcare Mater. https://doi.org/10.1002/adhm.202403107 (2025).

90. Luobin, L. et al. Nanomedicine-induced programmed cell death in cancer therapy: mechanisms and perspectives. Cell Death Discov. https://doi.org/10.1038/s41420-024-02121-0 (2024).

91. Zhang, Z., Tang, Y., Luo, D., Qiu, J. & Chen, L. Advances in nanotechnology for targeting cancer-associated fibroblasts: a review of multi-strategy drug delivery and preclinical insights. APL Bioengin. https://doi.org/10.1063/5.0244706 (2025).

92. Wu, H., Zhang, T., Li, N. & Gao, J. Cell membrane-based biomimetic vehicles for effective central nervous system target delivery: insights and challenges. J. Control. Release 360, 169–184 (2023).

    Google Scholar 

93. Cai, Q., Guo, R., Chen, D., Deng, Z. & Gao, J. SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials. J. Nanobiotechnol. https://doi.org/10.1186/s12951-025-03254-9 (2025).

94. Zheng, L. et al. Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment. Cancer Drug Resist. https://doi.org/10.20517/cdr.2024.107 (2024).

95. Mamidi, N., Franco De Silva, F. & Orash Mahmoudsalehi, A. Advanced disease therapeutics using engineered living drug delivery systems. Nanoscale 17, 7673–7696 (2025).

    Google Scholar 

96. Gao, Z., Wan, D., Luo, M., Wei, X. Application of nanomedicines in tumor immunotherapy. J. Mol. Cell Biol. https://doi.org/10.1093/jmcb/mjae055 (2024).

97. Zhou, Y. & Chen, L., Wang, T. Nanoparticles in gynecologic cancers: a bibliometric and visualization analysis. Front. Oncol. https://doi.org/10.3389/fonc.2024.1465987 (2025).

98. Wei, Y. et al. Nanomedicines targeting tumor cells or tumor-associated macrophages for combinatorial cancer photodynamic therapy and immunotherapy: strategies and influencing factors. Int. J. Nanomedicine 19, 10129–10144 (2024).

    Google Scholar 

99. Nooraei, S. et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. https://doi.org/10.1186/s12951-021-00806-7 (2021).

100. Wu, P. et al. Nanoparticle-based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications. Pharmaceutics 14, 1990 (2022).

     Google Scholar 

101. Luo, K. et al. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo. J. Control. Release 326, 25–37 (2020).

     Google Scholar 

102. Liu, Y. & Wang, H. Biomarkers and targeted therapy for cancer stem cells. Trends Pharmacol. Sci. 45, 56–66 (2024).

     Google Scholar 

103. Ma, X. et al. Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy. Mater. Today Bio 21, 100698 (2023).

     Google Scholar 

104. Fu, Q. & Fu, L. Engineering nanosystems for regulating reproductive health in women. Theranostics 15, 439–459 (2025).

     Google Scholar 

105. Xi, Y. et al. Amplifying “eat me signal” by immunogenic cell death for potentiating cancer immunotherapy. Immunol. Rev. 321, 94–114 (2023).

     Google Scholar 

106. Zhang, J., Wang, F., Sun, Z., Ye, J. & Chu, H. Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy. J. Nanobiotechnol. https://doi.org/10.1186/s12951-025-03236-x (2025).

107. Cassani, M. et al. Unraveling the role of the tumor extracellular matrix to inform nanoparticle design for nanomedicine. Adv. Sci. https://doi.org/10.1002/advs.202409898 (2024).

108. Mahri, S. et al. Nanomedicine approaches for autophagy modulation in cancer therapy. Small Sci. https://doi.org/10.1002/smsc.202400607 (2025).

109. Yan, Y. & Ding, H. pH-responsive nanoparticles for cancer immunotherapy: a brief review. Nanomaterials 10, 1613 (2020).

     Google Scholar 

110. Yao, Y. et al. Engineered CAF-cancer cell hybrid membrane biomimetic dual-targeted integrated platform for multi-dimensional treatment of ovarian cancer. J. Nanobiotechnol. https://doi.org/10.1186/s12951-025-03165-9 (2025).

111. Guo, Y., Hu, P. & Shi, J. Nanomedicine remodels tumor microenvironment for solid tumor immunotherapy. J. Am. Chem. Soc. 146, 10217–10233 (2024).

     Google Scholar 

112. Zhang, Z., Wang, R. & Chen, L. Drug delivery system targeting cancer-associated fibroblast for improving immunotherapy. Int. J. Nannomedicine 20, 483–503 (2025).

     Google Scholar 

113. Xu, T., Liu, Z., Huang, L., Jing, J. & Liu, X. Modulating the tumor immune microenvironment with nanoparticles: a sword for improving the efficiency of ovarian cancer immunotherapy. Front. Immunol. https://doi.org/10.3389/fimmu.2022.1057850 (2022).

114. Zhang, Y. et al. Advanced carriers for precise delivery and therapeutic mechanisms of traditional chinese medicines: integrating spatial multi-omics and delivery visualization. Adv. Healthcare Materials. https://doi.org/10.1002/adhm.202403698 (2025).

115. Chen, Z. et al. Targeted mitochondrial nanomaterials in biomedicine: advances in therapeutic strategies and imaging modalities. Acta Biomater. 186, 1–29 (2024).

     Google Scholar 

116. Avgoustakis, K. & Angelopoulou, A. Biomaterial-based responsive nanomedicines for targeting solid tumor microenvironments. Pharmaceutics 16, 179 (2024).

     Google Scholar 

117. Luo, R., Le, H., Wu, Q. & Gong, C. Nanoplatform-based in vivo gene delivery systems for cancer therapy. Small. https://doi.org/10.1002/smll.202312153 (2024).

118. Zhao, J., Shi, Y. & Cao, G. The application of single-cell RNA sequencing in the inflammatory tumor microenvironment. Biomolecules 13, 344 (2023).

     Google Scholar 

119. Kunachowicz, D., Kłosowska, K., Sobczak, N. & Kepinska, M. Applicability of quantum dots in breast cancer diagnostic and therapeutic modalities—a state-of-the-art review. Nanomaterials 14, 1424 (2024).

     Google Scholar 

120. Park, H., Saravanakumar, G., Kim, J., Lim, J. & Kim, W. J. Tumor microenvironment sensitive nanocarriers for bioimaging and therapeutics. Adv. Healthcare Mater. https://doi.org/10.1002/adhm.202000834 (2020).

121. Zeng, Y. et al. Hypoxia-activated prodrugs and redox-responsive nanocarriers. Int. J. Nanomedicine 13, 6551–6574 (2018).

     Google Scholar 

122. Son, J. et al. MMP-responsive nanomaterials. Biomater. Sci. 11, 6457–6479 (2023).

     Google Scholar 

123. Wlodarczyk, M. T. et al. Pt(II)-PLGA hybrid in a ph-responsive nanoparticle system targeting ovarian cancer. Pharmaceutics 15, 607 (2023).

     Google Scholar 

124. Zhou, M. et al. Nanovesicles loaded with a TGF-β receptor 1 inhibitor overcome immune resistance to potentiate cancer immunotherapy. Nat. Commun. https://doi.org/10.1038/s41467-023-39035-x (2023).

125. Tian, S.-C. et al. Self-oxygenating nanoplatform integrating CRISPR/Cas9 gene editing and immune activation for highly efficient photodynamic therapy. J. Colloid Interface Sci. 693, 137632 (2025).

     Google Scholar 

126. Li, Y. et al. A nanoscale natural drug delivery system for targeted drug delivery against ovarian cancer: action mechanism, application enlightenment and future potential. Front. Immunol. https://doi.org/10.3389/fimmu.2024.1427573 (2024).

127. Liu, W. et al. Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics. Clin. Exp. Metastasis 41, 313–332 (2023).

     Google Scholar 

128. Li, Y., Stanojevic, S. & Garmire, L. X. Emerging artificial intelligence applications in spatial transcriptomics analysis. Comput. Struct. Biotechnol. J. 20, 2895–2908 (2022).

     Google Scholar 

129. Kiessling, P. & Kuppe, C. Spatial multi-omics: novel tools to study the complexity of cardiovascular diseases. Genome Med. https://doi.org/10.1186/s13073-024-01282-y (2024).

130. Zhong, Z. et al. Cell membrane coated nanoparticles as a biomimetic drug delivery platform for enhancing cancer immunotherapy. Nanoscale 16, 8708–8738 (2024).

     Google Scholar 

131. Wang, Y. et al. Smart nanoplatforms responding to the tumor microenvironment for precise drug delivery in cancer therapy. Int. J. Nanomedicine 19, 6253–6277 (2024).

     Google Scholar 

132. Peng, X. et al. Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy. Acta Pharm. Sin. B 14, 3432–3456 (2024).

     Google Scholar 

133. Gu, X. et al. Revisiting the CXCL13/CXCR5 axis in the tumor microenvironment in the era of single-cell omics: implications for immunotherapy. Cancer Lett. 605, 217278 (2024).

     Google Scholar 

134. Shi, B., Du, M. & Chen, Z. Advances in tumor immunotherapy targeting macrophages. Expert Rev. Clin. Immunol. 21, 259–276 (2024).

     Google Scholar 

135. Ji, Y. et al. Triggered cascade-activation nanoplatform to alleviate hypoxia for effective tumor immunotherapy guided by NIR-II imaging. ACS Nano 18, 31421–31434 (2024).

     Google Scholar 

136. Lyu, P. et al. Advances in targeting cancer-associated fibroblasts through single-cell spatial transcriptomic sequencing. Biomark Res. https://doi.org/10.1186/s40364-024-00622-9 (2024).

137. Li, Z. et al. Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress. Front. Pharmacol. https://doi.org/10.3389/fphar.2024.1382256 (2024).

138. Li, H. et al. Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation. Chem. Soc. Rev. 52, 47–96 (2023).

     Google Scholar 

139. Zhou, X. et al. Small extracellular vesicles: the origins, current status, future prospects, and applications. Stem Cell Res Ther. https://doi.org/10.1186/s13287-025-04330-5 (2025).

140. Xu, Y., Sun, D., He, J., Yao, Q. Cancer-associated fibroblasts in ovarian cancer: research progress. Front. Oncol. https://doi.org/10.3389/fonc.2025.1504762 (2025).

141. Zhang, F. et al. Cellular senescence and metabolic reprogramming: Unraveling the intricate crosstalk in the immunosuppressive tumor microenvironment. Cancer Commun. 44, 929–966 (2024).

     Google Scholar 

142. Lan, H. et al. Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer. Front. Immunol. https://doi.org/10.3389/fimmu.2025.1539616 (2025).

143. Corradetti, B., Pisano, S., Conlan, R. S. & Ferrari, M. Nanotechnology and immunotherapy in ovarian cancer: tracing new landscapes. J. Pharmacol. Exp. Ther. 370, 636–646 (2019).

     Google Scholar 

144. Truxova, I., Cibula, D., Spisek, R. & Fucikova, J. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma. J. Immunother. Cancer 11, e005968 (2023).

     Google Scholar 

145. Zheng, J. et al. Tumor-associated macrophages in nanomaterial-based anti-tumor therapy: as target spots or delivery platforms. Front. Bioeng. Biotechnol. https://doi.org/10.3389/fbioe.2023.1248421 (2023).

146. Li, S.-L. et al. Nanomaterials-involved tumor-associated macrophages’ reprogramming for antitumor therapy. ACS Nano 18, 7769–7795 (2024).

     Google Scholar 

147. Kaur, P., Singh, S. K., Mishra, M. K., Singh, S. & Singh, R. Nanotechnology for boosting ovarian cancer immunotherapy. J. Ovarian Res. https://doi.org/10.1186/s13048-024-01507-z. (2024).

148. Jiang, A., He, W. & Yao, Y. Editorial: overcoming obstacles of cancer immunotherapy: the important role of emerging nanomedicine. Front. Oncol. https://doi.org/10.3389/fonc.2024.1406244 (2024).

149. Li, W.-Y. et al. A reactive oxygen species-responsive covalent organic framework for tumor combination therapy. Chem. Commun. 59, 5423–5426 (2023).

     Google Scholar 

150. Chae, Y. K. et al. SWOG/NCI phase II dual anti-CTLA-4/PD-1 blockade in rare tumors: nonepithelial ovarian cancer. Clin. Cancer Res. 30, 5593–5600 (2024).

     Google Scholar 

151. Denisenko, E. et al. Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones. Nat. Commun. https://doi.org/10.1038/s41467-024-47271-y (2024).

152. Lin, Y., Zhou, X., Ni, Y., Zhao, X. & Liang, X. Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: a novel orientation for immunotherapy. Front. Immunol. https://doi.org/10.3389/fimmu.2022.1030831 (2022).

153. Yang, M., Chen, G., Gao, K. & Wang, Y. Tumor immunometabolism characterization in ovarian cancer with prognostic and therapeutic implications. Front. Oncol. https://doi.org/10.3389/fonc.2021.622752 (2021).

154. Zarrella, S. et al. Endoplasmic reticulum stress and its role in metabolic reprogramming of cancer. Metabolites 15, 221 (2025).

     Google Scholar 

155. Almeida-Nunes, D. L., Mendes-Frias, A., Silvestre, R., Dinis-Oliveira, R. J. & Ricardo, S. Immune tumor microenvironment in ovarian cancer ascites. IJMS 23, 10692 (2022).

     Google Scholar 

156. Johnson, R. et al. Barriers to immunotherapy in ovarian cancer: metabolic, genomic, and immune perturbations in the tumour microenvironment. Cancers 13, 6231 (2021).

     Google Scholar 

157. Li, R. et al. Nanotherapeutics for macrophage network modulation in tumor microenvironments: targets and tools. Int. J. Nanomedicine 19, 13615–13651 (2024).

     Google Scholar 

158. Shae, D. et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14, 269–278 (2019).

     Google Scholar 

159. Ringel, A. E. et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell 183, 1848–1866.e26 (2020).

     Google Scholar 

160. Petriaggi, L. et al. Iron fist in a velvet glove: class IV ferroptosis inducers as a novel strategy to target ovarian cancer. Front. Biosci. https://doi.org/10.31083/fbl39675 (2025).

161. Castro, C. M. et al. Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies. Cancer Metastasis Rev. 34, 75–82 (2014).

     Google Scholar 

162. Kuang, Y. et al. Advances in self-assembled nanotechnology in tumor therapy. Colloids Surf. B Biointerfaces 237, 113838 (2024).

     Google Scholar 

163. Yeh, C. Y. et al. Mapping spatial organization and genetic cell-state regulators to target immune evasion in ovarian cancer. Nat. Immunol. 25, 1943–1958 (2024).

     Google Scholar 

164. Han, X. et al. Single-cell and spatial transcriptome sequencing uncover a platinum-resistant cluster overexpressed TACSTD2 in high-grade serous ovarian cancer. J. Cancer 15, 3427–3440 (2024).

     Google Scholar 

165. Wu, Y., Cheng, Y., Wang, X., Fan, J. & Gao, Q. Spatial omics: navigating to the golden era of cancer research. Clin. Transl. Med. https://doi.org/10.1002/ctm2.696 (2022).

166. Martin, J. D., Cabral, H., Stylianopoulos, T. & Jain, R. K. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 17, 251–266 (2020).

     Google Scholar 

167. Zhang, M.-R. et al. Advancements in stimulus-responsive co-delivery nanocarriers for enhanced cancer immunotherapy. Int. J. Nanomedicine 19, 3387–3404 (2024).

     Google Scholar 

168. Feng, Q. & Xiao, K. Nanoparticle-mediated delivery of STAT3 inhibitors in the treatment of lung cancer. Pharmaceutics 14, 2787 (2022).

     Google Scholar 

169. Li, F., Wang, Y., Chen, D. & Du, Y. Nanoparticle-based immunotherapy for reversing T-cell exhaustion. Int J. Mol. Sci. 25, 1396 (2024).

     Google Scholar 

170. Elhanani, O., Ben-Uri, R. & Keren, L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell 41, 404–420 (2023).

     Google Scholar 

171. Rea, A. et al. Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression. Nat. Immunol. 26, 582–594 (2025).

     Google Scholar 

172. Huang, G. et al. Hypoxia-responsive covalent organic framework nanoplatform for breast-cancer-targeted cocktail immunotherapy via triple therapeutic switch mechanisms. Small. https://doi.org/10.1002/smll.202407553 (2025).

173. Luo, Y. et al. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell 187, 4905–4925.e24 (2024).

     Google Scholar 

174. Lin, Q. et al. Advancing ovarian cancer therapeutics: the role of targeted drug delivery systems. Int. J. Nanomedicine 19, 9351–9370 (2024).

     Google Scholar 

175. Li, Y., Jeon, J. & Park, J. H. Hypoxia-responsive nanoparticles for tumor-targeted drug delivery. Cancer Lett. 490, 31–43 (2020).

     Google Scholar 

176. Dutta, D. et al. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model. PLoS One 19, e0297749 (2024).

     Google Scholar 

177. Pranjol, Z. I. & Whatmore, J. L. Cathepsin D in the tumor microenvironment of breast and ovarian cancers. Adv. Exp. Med. Biol. 1259:1–16 (2020).

178. Li, G., Zhang, J., Zhang, S., Teng, L. & Sun, F. Multifunctional nanoadjuvant-driven microenvironment modulation for enhanced photothermal immunotherapy in breast cancer. J. Control. Release 362, 309–324 (2023).

     Google Scholar 

179. Zhang, H. et al. Self-supervised deep learning for highly efficient spatial immunophenotyping. eBioMedicine 95, 104769 (2023).

     Google Scholar 

180. Dhainaut, M. et al. Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell 185, 1223–1239.e20 (2022).

     Google Scholar 

181. Desbois, M. et al. Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. Nat. Commun. https://doi.org/10.1038/s41467-020-19408-2 (2020).

182. Liu, X. et al. Spatial multi-omics: deciphering technological landscape of integration of multi-omics and its applications. J. Hematol. Oncol. https://doi.org/10.1186/s13045-024-01596-9 (2024).

183. Yang, B. et al. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. Cell Rep. Med. 3, 100856 (2022).

     Google Scholar 

184. Wang, Y. et al. Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer. Cancer Res. 82, 3903–3916 (2022).

     Google Scholar 

185. Li, Q., Xiao, X., Feng, J., Yan, R. & Xi, J. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer. Front. Endocrinol. https://doi.org/10.3389/fendo.2023.1196094 (2023).

186. Regner, M. J. et al. A multi-omic single-cell landscape of human gynecologic malignancies. Mol. Cell 81, 4924–4941.e10 (2021).

     Google Scholar 

187. Xie, T. et al. Artificial intelligence: illuminating the depths of the tumor microenvironment. J. Transl. Med. https://doi.org/10.1186/s12967-024-05609-6 (2024).

188. Couture, H. D. Deep learning-based prediction of molecular tumor biomarkers from H&E: a practical review. J. Pers.Med. 12, 2022 (2022).

     Google Scholar 

189. Ng, C. W., Wong, K.-K., Lawson, B. C., Ferri-Borgogno, S. & Mok, S. C. Spatial transcriptome reveals histology-correlated immune signature learnt by deep learning attention mechanism on H&E-stained images for ovarian cancer prognosis. J. Transl. Med. https://doi.org/10.1186/s12967-024-06007-8 (2025).

190. Halawani, R., Buchert, M. & Chen, Y.-P. P. Deep learning exploration of single-cell and spatially resolved cancer transcriptomics to unravel tumour heterogeneity. Comput. Biol. Med. 164, 107274 (2023).

     Google Scholar 

191. Bera, K., Braman, N., Gupta, A., Velcheti, V. & Madabhushi, A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat. Rev. Clin. Oncol. 19, 132–146 (2021).

     Google Scholar 

192. Xing, W. et al. Artificial intelligence predicts lung cancer radiotherapy response: a meta-analysis. Artif. Intell. Med. 142, 102585 (2023).

     Google Scholar 

193. Hurkmans, C. et al. A joint ESTRO and AAPM guideline for development, clinical validation and reporting of artificial intelligence models in radiation therapy. Radiother. Oncol. 197, 110345 (2024).

     Google Scholar 

194. Zhang, B. et al. Harnessing artificial intelligence to improve clinical trial design. Commun. Med. https://doi.org/10.1038/s43856-023-00425-3 (2023).

195. Walsh, L. A. & Quail, D. F. Decoding the tumor microenvironment with spatial technologies. Nat. Immunol. 24, 1982–1993 (2023).

     Google Scholar 

196. Xu, M., Chen, Z., Zheng, J., Zhao, Q. & Yuan, Z. Artificial intelligence-aided optical imaging for cancer theranostics. Semin. Cancer Biol. 94, 62–80 (2023).

     Google Scholar 

197. Hai, L., Jiang, Z., Zhang, H. & Sun, Y. From multi-omics to predictive biomarker: AI in tumor microenvironment. Front. Immunol. https://doi.org/10.3389/fimmu.2024.1514977 (2024).

198. Qi, L., Li, Z., Liu, J. & Chen, X. Omics-enhanced nanomedicine for cancer therapy. Adv. Mater. https://doi.org/10.1002/adma.202409102 (2024).

199. Kejun, D. et al. Multifunctional DNA nano-sponge system for targeted sensitization of ovarian cancer chemotherapy via metabolic reprogramming and ferroptosis induction. J. Control. Release 382, 113663 (2025).

     Google Scholar 

200. Yu, Y. et al. Biodegradable polymer with effective near-infrared-II absorption as a photothermal agent for deep tumor therapy. Adv. Mater. https://doi.org/10.1002/adma.202105976 (2021).

201. Li, G. et al. Highly efficient synergistic chemotherapy and magnetic resonance imaging for targeted ovarian cancer therapy using hyaluronic acid-coated coordination polymer nanoparticles. Adv. Sci. https://doi.org/10.1002/advs.202309464 (2024).

202. Allesøe, R. L. et al. Discovery of drug–omics associations in type 2 diabetes with generative deep-learning models. Nat. Biotechnol. 41, 399–408 (2023).

     Google Scholar 

203. Qu, H. et al. Programmed-response cross-linked nanocarrier for multidrug-resistant ovarian cancer treatment. J. Control. Release 357, 274–286 (2023).

     Google Scholar 

204. Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108–133 (2021).

     Google Scholar 

205. Wang, G. et al. ROS-responsive thioether-containing hyperbranched polymer micelles for light-triggered drug release. SmartMat 3, 522–531 (2022).

     Google Scholar 

206. Ghaffari, S., Khalili, N. & Rezaei, N. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy. J. Exp. Clin. Cancer Res. https://doi.org/10.1186/s13046-021-02076-5 (2021).

207. Vora, L. K. et al. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics 15, 1916 (2023).

     Google Scholar 

208. Wang, T. et al. snPATHO-seq, a versatile FFPE single-nucleus RNA sequencing method to unlock pathology archives. Commun. Biol. https://doi.org/10.1038/s42003-024-07043-2 (2024).

209. Zhao, E. et al. Spatial transcriptomics at subspot resolution with BayesSpace. Nat. Biotechnol. 39, 1375–1384 (2021).

     Google Scholar 

210. Zhang, L., Cascio, S., Mellors, J. W., Buckanovich, R. J. & Osmanbeyoglu, H. U. Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer. Commun. Biol. https://doi.org/10.1038/s42003-023-05733-x (2024).

211. Xu, J. et al. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. Clin. Cancer Res. 28, 3590–3602 (2022).

     Google Scholar 

212. Masatti, L. et al. The unveiled mosaic of intra-tumor heterogeneity in ovarian cancer through spatial transcriptomic technologies: a systematic review. Transl. Res. 273, 104–114 (2024).

     Google Scholar 

213. Laury, A. R. et al. Opening the Black Box: spatial transcriptomics and the relevance of artificial intelligence-detected prognostic regions in high-grade serous carcinoma. Mod. Pathol. 37, 100508 (2024).

     Google Scholar 

214. Kobelyatskaya, A., Tregubova, A., Palicelli, A., Badlaeva, A. & Asaturova, A. OVsignGenes: a gene expression-based neural network model estimated molecular subtype of high-grade serous ovarian carcinoma. Cancers 16, 3951 (2024).

     Google Scholar 

215. Carvalho, R. F. et al. Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer. Cell. Commun. Signal. https://doi.org/10.1186/s12964-022-00991-4 (2022).

216. Wang, Z., Yang, L., Su, X., Wu, X. & Su, R. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma. J. Gene Med. https://doi.org/10.1002/jgm.3504 (2023).

217. Hatamikia, S. et al. Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers. Eur. Radiol. Exp. https://doi.org/10.1186/s41747-023-00364-7 (2023).

218. Zhou, Z. et al. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond. Mol. Cancer. https://doi.org/10.1186/s12943-024-02047-2 (2024).

219. Huang, S. et al. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. Mol. Cancer. https://doi.org/10.1186/s12943-023-01783-1 (2023).

220. Zhang, Y. et al. Spatial omics techniques and data analysis for cancer immunotherapy applications. Curr. Opin. Biotechnol. 87, 103111 (2024).

     Google Scholar 

221. D’Orsi, L. et al. Recent advances in artificial intelligence to improve immunotherapy and the use of digital twins to identify prognosis of patients with solid tumors. Int. J. Mol. Sci. 25, 11588 (2024).

     Google Scholar 

222. Emens, L. A. et al. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision. J. Immunother. Cancer 12, e009063 (2024).

     Google Scholar 

223. Tian, J., Bai, X. & Quek, C. Single-cell informatics for tumor microenvironment and immunotherapy. Int. J. Mol. Sci. 25, 4485 (2024).

     Google Scholar 

224. Ran, X. et al. Single-cell transcriptomics reveals the heterogeneity of the immune landscape of IDH-wild-type high-grade gliomas. Cancer Immunol. Res. 12, 232–246 (2023).

     Google Scholar 

225. Chen, J., Yang, L., Ma, Y. & Zhang, Y. Recent advances in understanding the immune microenvironment in ovarian cancer. Front. Immunol. https://doi.org/10.3389/fimmu.2024.1412328 (2024).

226. Dumitru, A., Dobrica, E.-C., Croitoru, A., Cretoiu, S. M. & Gaspar, B. S. Focus on PD-1/PD-L1 as a therapeutic target in ovarian cancer. IJMS 23, 12067 (2022).

     Google Scholar 

227. Guo, Q. Y. et al. IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3/HIF-1α pathway. Med. Oncol. https://doi.org/10.1007/s12032-024-02328-2 (2024).

228. Xue, J., Li, R., Gao, D., Chen, F. & Xie, H. CXCL12/CXCR4 axis-targeted dual-functional nano-drug delivery system against ovarian cancer. Int. J. Nanomedicine. 15, 5701–5718 (2020).

229. Ying, X., Zheng, X., Zhang, X., Yin, Y. & Wang, X. Kynurenine in IDO1high cancer cell-derived extracellular vesicles promotes angiogenesis by inducing endothelial mitophagy in ovarian cancer. J. Transl. Med. https://doi.org/10.1186/s12967-024-05054-5 (2024).

230. Kumari, A. et al. TGFβ signaling networks in ovarian cancer progression and plasticity. Clin. Exp. Metastasis 38, 139–161 (2021).

     Google Scholar 

231. Tan, L. et al. Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review. Future Oncol. 20, 1943–1960 (2024).

     Google Scholar 

232. El-Mais, N., Fakhoury, I., Abdellatef, S., Abi-Habib, R. & El-Sibai, M. Human recombinant arginase I [HuArgI (Co)-PEG5000]-induced arginine depletion inhibits ovarian cancer cell adhesion and migration through autophagy-mediated inhibition of RhoA. J. Ovarian Res. https://doi.org/10.1186/s13048-021-00767-3 (2021).

233. Hao, F. et al. Reverse-engineering the FLT3-PI3K/AKT axis to enhance TILs function and improve prognosis in ovarian and cervical cancers. J. Ovarian Res. https://doi.org/10.1186/s13048-025-01592-8 (2025).

234. Hu, J. et al. SpaGCN: Integrating gene expression, spatial location and histology to identify spatial domains and spatially variable genes by graph convolutional network. Nat. Methods 18, 1342–1351 (2021).

     Google Scholar 

235. Dong, K. & Zhang, S. Deciphering spatial domains from spatially resolved transcriptomics with an adaptive graph attention auto-encoder. Nat. Commun. https://doi.org/10.1038/s41467-022-29439-6 (2022).

236. Torabi, M. et al. Fabrication of mesoporous silica nanoparticles for targeted delivery of sunitinib to ovarian cancer cells. Bioimpacts. https://doi.org/10.34172/bi.2023.25298 (2023).

237. Marwedel, B., De May, H. & Anderson, L. et al. TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer. Adv. Healthc Mater. 14, e2402966. https://doi.org/10.1002/adhm.202402966 (2025).

238. Noureddine, A., Marwedel, B., Tang, L., Medina, L. Y. & Serda, R. E. Specific tumor localization of immunogenic lipid-coated mesoporous silica nanoparticles following intraperitoneal administration in a mouse model of serous epithelial ovarian cancer. Cancers 15, 4626 (2023).

     Google Scholar 

Download references